Lambert Michele P
Division of Hematology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA; and Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):692-699. doi: 10.1182/hematology.2024000596.
Treatment of immune thrombocytopenia (ITP) has evolved over the last 20 years in response to our increased understanding of the pathophysiology of this complex immune disorder. New treatments in development have taken advantage of our evolving understanding of the biology of this disease to target new mechanisms and expand the available ways in which to approach patients with this disorder. This review focuses on novel therapeutics in the ITP pipeline and discusses the pathophysiology of ITP that has led to their development.
在过去20年里，随着我们对这种复杂免疫疾病病理生理学的深入了解，免疫性血小板减少症（ITP）的治疗方法不断演变。新研发的治疗方法利用了我们对该疾病生物学认识的不断发展，以针对新机制，并拓展治疗该疾病患者的可用方法。本综述聚焦于ITP研发中的新型疗法，并讨论了促使这些疗法得以研发的ITP病理生理学。
